BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Quintessence Biosciences, Inc. Presents Efficacy Data for Next Generation Evade™ Ribonucleases at Cancer Meeting


10/23/2008 3:26:35 PM

GENEVA, SWITZERLAND AND MADISON, WI – Dr. Laura Strong of Quintessence Biosciences, Inc. presented information about the company’s next generation Evade™ Ribonucleases at the International Conference on Molecular Targets and Cancer Therapeutics - the premier international meeting featuring novel cancer therapeutics. Dr. Strong’s presentation, Anti-cancer activity of human ribonuclease conjugates with enhanced pharmacokinetics profiles, provides data for conjugates made from the Company’s lead candidate QBI-139.

QBI-139 is a potent anticancer agent based on the EVade™ Ribonuclease technology. The technology provides an opportunity to attack RNA, an exciting new cancer drug target, with analogs of the human pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown an exceptional safety profile and outstanding tumor growth inhibition in vivo against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors. Of approximately 40 different EVade™ Ribonucleases tested to date, QBI-139 had the best therapeutic index as well as the broadest efficacy in multiple tumor lines.

Quintessence projects a Phase 1 clinical trial for QBI-139 will begin in the upcoming months, subject to U.S. Food and Drug Administration (FDA) review.

“The success of the next generation Evade™ Ribonuclease conjugates significantly broadens the potential impact of our drug candidates,” said Quintessence Biosciences CEO Ralph Kauten. “Conjugates of proteins with water soluble polymers have historically provided safer and more effective products relative to the unconjugated proteins.”

About Quintessence Biosciences, Inc.

Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is anticipated to enter a Phase 1 clinical trial soon. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About the International Conference on Molecular Targets and Cancer Therapeutics

Three of the world’s leading cancer organizations:

The European Organization for Research and Treatment of Cancer

The USA’s National Cancer Institute

The American Association for Cancer Research

will join forces in Geneva Switzerland from October 21-24, 2008 to provide a platform for presenting the recent advances in the early development of promising new compounds in different stages of pre-clinical and clinical research to around 2,200 international experts in the field.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES